Reduced NMN (XJY-NMNH 95%)
CAS# 108347-85-9
NMNH is a reduced form of nicotinamide mononucleotide (NMN), which is the NAD+ direct precursor and boosts NAD+ level in our body.
Quantity
Researchers use NMNH in vitro experiments to detect its ability to enhance NAD+ levels in cells. Adding different concentrations NMNH to mouse liver cells, it was found that NMNH increased the level of NAD+ in cells, but also accelerated the rate of increase in NAD+ concentration and Suppresses Glycolysis, the TCA Cycle, and Cell Growth.
Product Detail
| Product name | NMNH, Reduced Nicotinamide Mononucleotide |
| Synonyms | Reduced β-NMN, reduced β-Nicotinamide monophosphate, reduced NMN, reduced Nicotinamide-1-ium-1-β-D-ribofuranoside 5′-phosphate |
| CAS number | 108347-85-9 |
| Molecular Formula | C11H17N2O8P |
| Molecular weight | 335.23 |
| Appearance/color | Yellowish powder |
| Specifications | >90% (HPLC) |
| solubility | soluble in water |
| Stability | Sealed package, dry and away from light, stored at -25℃~-15℃ |
| Shelf life | 24 months |
According to the study, scientists identify NMNH as a new and potent NAD+ precursor in vitro and in vivo, and con-firm the existence of a novel pathway for the recycling of reduced precursors to NAD+.
Rubén Zapata-Pérez, Alessandra Tammaro, Bauke V Schomakers et al.(2021). Reduced nicotinamide mononucleotide is a new and potent NAD+ precursor in mammalian cells and mice. FASEB J. 2021 Apr;35(4):e21456. doi: 10.1096/fj.202001826R.
| IMPORTANT: This infomation is not intended to diagnose, treat, cure, or prevent any disease, and it should not be used by anyone who is pregnant or under the care of a medical practitioner. Please consult your physician about which supplements may or may not be right for you. |
More option to consider
